Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716066 · ClinicalTrials.gov registry record · Phase 2
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
A Phase 2 study of Autoimmune Disease and Stiff Person Syndrome, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 3
- Study locations
NCT00716066 is a Phase 2 study of Autoimmune Disease and Stiff Person Syndrome that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 53 participants, below the 1,506-participant average among 10 other Autoimmune Disease trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00716066, a Phase 2 study of Autoimmune Disease and Stiff Person Syndrome, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.
Conditions Studied
Interventions
- DRUG Etoposide
- BIOLOGICAL Anti-Thymocyte Globulin
- DRUG Cytarabine
- DRUG Carmustine
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
Study Locations (3)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
- Swedish Medical Center-First Hill - Seattle
Colorado
- Colorado Blood Cancer Institute - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-06 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716066
The ClinicalTrials.gov registry entry for NCT00716066 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,506-participant average among 10 other Autoimmune Disease trials with a reported enrollment target (96% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Autoimmune Disease appearing as the primary indexed condition, and to 5 interventions - of which Etoposide is the first listed.
NCT00716066 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Washington, Colorado.
Frequently Asked Questions
What is clinical trial NCT00716066 about?
NCT00716066 is a clinical study titled "Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases". This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurologi...
What is the current status of trial NCT00716066?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2008-06. Estimated completion is 2030-01-31.
What conditions does trial NCT00716066 study?
This clinical trial studies the following conditions: Autoimmune Disease, Stiff Person Syndrome, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant.
What interventions are being tested in trial NCT00716066?
The interventions under investigation include: Etoposide (DRUG), Anti-Thymocyte Globulin (BIOLOGICAL), Cytarabine (DRUG), Carmustine (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00716066?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00716066 being conducted?
This trial has 3 study locations across Colorado, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Natural History of Bronchiectasis
RECRUITING
-
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.